Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Biogen Inc (BIIB)

Biogen Inc (BIIB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 26,950,822
  • Shares Outstanding, K 146,759
  • Annual Sales, $ 9,891 M
  • Annual Income, $ 1,293 M
  • EBIT $ 2,377 M
  • EBITDA $ 3,451 M
  • 60-Month Beta 0.15
  • Price/Sales 2.69
  • Price/Cash Flow 8.02
  • Price/Book 1.46

Options Overview Details

View History
  • Implied Volatility 35.97% (-1.24%)
  • Historical Volatility 25.49%
  • IV Percentile 57%
  • IV Rank 22.59%
  • IV High 64.86% on 04/09/25
  • IV Low 27.55% on 01/07/26
  • Expected Move (DTE 3) 4.63 (2.52%)
  • Put/Call Vol Ratio 0.18
  • Today's Volume 503
  • Volume Avg (30-Day) 1,094
  • Put/Call OI Ratio 0.94
  • Today's Open Interest 38,068
  • Open Int (30-Day) 50,506
  • Expected Range 179.14 to 188.40

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 35 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 3.05
  • Number of Estimates 26
  • High Estimate 4.68
  • Low Estimate 1.66
  • Prior Year 3.02
  • Growth Rate Est. (year over year) +0.99%

Price Performance

See More
Period Period Low Period High Performance
1-Month
180.47 +1.94%
on 03/20/26
196.73 -6.49%
on 02/25/26
-11.16 (-5.72%)
since 02/24/26
3-Month
160.36 +14.72%
on 01/20/26
202.41 -9.11%
on 02/06/26
+7.64 (+4.33%)
since 12/24/25
52-Week
110.04 +67.18%
on 04/09/25
202.41 -9.11%
on 02/06/26
+42.37 (+29.92%)
since 03/24/25

Most Recent Stories

More News
Results from Real-World, Long-Term Treatment Persistence with LEQEMBI® (lecanemab-irmb) in the United States Presented at AD/PD™ 2026

Real-World LEQEMBI Data Shows Patients Choose to Stay on Long-Term Treatment

BIIB : 183.61 (-0.02%)
Biogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting

Late-breaking AMETHYST Part A study results to be presented, showing safety and efficacy of litifilimab in cutaneous lupus erythematosus (CLE) Litifilimab was recently granted Breakthrough Therapy Designation...

BIIB : 183.61 (-0.02%)
Biogen Stock: Is BIIB Outperforming the Healthcare Sector?

Biogen has outperformed its sector peers recently, and analysts remain moderately optimistic about the stock’s prospects.

XLV : 144.53 (-0.17%)
AMGN : 351.27 (+0.43%)
BIIB : 183.61 (-0.02%)
Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy

New Phase 1b data support the safety and effectiveness of salanersen over one year in children with SMA who had the potential for improvement due to suboptimal clinical status with prior gene therapy ...

BIIB : 183.61 (-0.02%)
Winners And Losers Of Q4: Biogen (NASDAQ:BIIB) Vs The Rest Of The Therapeutics Stocks

Winners And Losers Of Q4: Biogen (NASDAQ:BIIB) Vs The Rest Of The Therapeutics Stocks

BIIB : 183.61 (-0.02%)
Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences

Long-term data from DEVOTE/ONWARD studies show benefits of high dose nusinersen in people living with spinal muscular atrophy (SMA) New Phase 1b data further illustrate potential of salanersen in SMA,...

BIIB : 183.61 (-0.02%)
The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome

–Results show that targeting the underlying cause of Dravet syndrome with zorevunersen may improve outcomes for people with this rare, devastating genetic neurodevelopmental disease– ...

STOK : 32.11 (-3.86%)
BIIB : 183.61 (-0.02%)
The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome

–Results show that targeting the underlying cause of Dravet syndrome with zorevunersen may improve outcomes for people with this rare, devastating genetic neurodevelopmental disease– –Data support...

STOK : 32.11 (-3.86%)
BIIB : 183.61 (-0.02%)
Is Vertex Stock Outperforming the Dow?

Despite underperforming the Dow Jones Industrial Average over the past year, Vertex continues to earn moderate bullish support from analysts.

VRTX : 449.40 (-0.41%)
$DOWI : 46,228.91 (+0.04%)
BIIB : 183.61 (-0.02%)
Stoke Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine,...

STOK : 32.11 (-3.86%)
BIIB : 183.61 (-0.02%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Biogen Inc. is one of the world's leading biotechnology companies which focuses on developing innovative therapies for treating serious neurological and neurodegenerative diseases, including its core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, movement...

See More

Key Turning Points

3rd Resistance Point 186.76
2nd Resistance Point 185.88
1st Resistance Point 184.76
Last Price 183.61
1st Support Level 182.76
2nd Support Level 181.88
3rd Support Level 180.76

See More

52-Week High 202.41
Last Price 183.61
Fibonacci 61.8% 167.12
Fibonacci 50% 156.23
Fibonacci 38.2% 145.33
52-Week Low 110.04

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.